Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T J Simon

Showing results (11-20 of 28) with videos related to

Pageof 3
Sort By:
The American Journal of Gastroenterology|June 13, 1998
Effects of alendronate on gastric and duodenal mucosaF Lanza, M F Rack, T J Simon, et al.
Biochemistry|June 18, 1985
Chronic ethanol increases liver plasma membrane fluidityM A Polokoff, T J Simon, R A Harris, et al.
Medgenmed : Medscape General Medicine|April 20, 2002
Gastrointestinal medications and procedures in osteoarthritis patients treated with rofecoxib compared with nonselective NSAIDsD J Watson, S E Harper, P L Zhao, et al.
Journal of Cognitive Neuroscience|February 9, 1999
Neural evidence linking visual object enumeration and attentionK Sathian, T J Simon, S Peterson, et al.
Alimentary Pharmacology & Therapeutics|January 3, 2001
Review article: the gastrointestinal safety profile of rofecoxib, a highly selective inhibitor of cyclooxygenase-2, in humansC J Hawkey, L Jackson, S E Harper, et al.
Archives of Internal Medicine|October 21, 2000
Gastrointestinal tolerability of the selective cyclooxygenase-2 (COX-2) inhibitor rofecoxib compared with nonselective COX-1 and COX-2 inhibitors in osteoarthritisD J Watson, S E Harper, P L Zhao, et al.
Neuropsychologia|October 9, 2007
Overlapping numerical cognition impairments in children with chromosome 22q11.2 deletion or Turner syndromesT J Simon, Y Takarae, T DeBoer, et al.
Journal of Autism and Developmental Disorders|July 12, 2021
The Importance of Understanding Individual Differences of Emotion Regulation Abilities in 22q11.2 Deletion SyndromeL E Campbell, L Swaab, E E Freeman, et al.
Clinical Therapeutics|November 1, 1995
Acid suppression by famotidine 20 mg twice daily or 40 mg twice daily in preventing relapse of endoscopic recurrence of erosive esophagitisT J Simon, W G Roberts, R G Berlin, et al.
The American Journal of Medicine|September 7, 2000
A randomized trial measuring fecal blood loss after treatment with rofecoxib, ibuprofen, or placebo in healthy subjectsR H Hunt, B Bowen, E R Mortensen, et al.
Pageof 3

Showing results (11-20 of 28) with videos related to

Sort By:
Pageof 3
The American Journal of Gastroenterology|June 13, 1998
Effects of alendronate on gastric and duodenal mucosaF Lanza, M F Rack, T J Simon, et al.
Biochemistry|June 18, 1985
Chronic ethanol increases liver plasma membrane fluidityM A Polokoff, T J Simon, R A Harris, et al.
Medgenmed : Medscape General Medicine|April 20, 2002
Gastrointestinal medications and procedures in osteoarthritis patients treated with rofecoxib compared with nonselective NSAIDsD J Watson, S E Harper, P L Zhao, et al.
Journal of Cognitive Neuroscience|February 9, 1999
Neural evidence linking visual object enumeration and attentionK Sathian, T J Simon, S Peterson, et al.
Alimentary Pharmacology & Therapeutics|January 3, 2001
Review article: the gastrointestinal safety profile of rofecoxib, a highly selective inhibitor of cyclooxygenase-2, in humansC J Hawkey, L Jackson, S E Harper, et al.
Archives of Internal Medicine|October 21, 2000
Gastrointestinal tolerability of the selective cyclooxygenase-2 (COX-2) inhibitor rofecoxib compared with nonselective COX-1 and COX-2 inhibitors in osteoarthritisD J Watson, S E Harper, P L Zhao, et al.
Neuropsychologia|October 9, 2007
Overlapping numerical cognition impairments in children with chromosome 22q11.2 deletion or Turner syndromesT J Simon, Y Takarae, T DeBoer, et al.
Journal of Autism and Developmental Disorders|July 12, 2021
The Importance of Understanding Individual Differences of Emotion Regulation Abilities in 22q11.2 Deletion SyndromeL E Campbell, L Swaab, E E Freeman, et al.
Clinical Therapeutics|November 1, 1995
Acid suppression by famotidine 20 mg twice daily or 40 mg twice daily in preventing relapse of endoscopic recurrence of erosive esophagitisT J Simon, W G Roberts, R G Berlin, et al.
The American Journal of Medicine|September 7, 2000
A randomized trial measuring fecal blood loss after treatment with rofecoxib, ibuprofen, or placebo in healthy subjectsR H Hunt, B Bowen, E R Mortensen, et al.
Pageof 3